Revolution Medicines begins treating patients in Phase 3 RASolve 308 trial of zoldonrasib

Revolution Medicines has begun treating patients in its Phase 3 RASolve 308 trial, evaluating zoldonrasib as a first-line treatment for patients with metastatic RAS G12D non-small cell lung cancer.

Detected & updated continuously · Source: Nebula